Dr Boreham’s diagnosis:
When it comes to comparative companies, Invex’s own material avers to the ASX-listed Paradigm Biopharmaceuticals (ASXAR) and Clinuvel Pharmaceuticals (ASX:CUV).Paradigm also repurposes a blood-thinning drug for osteoarthritis pain. Paradigm is also phase II stage and has a $500m-plus market valuation.Clinuvel had orphan drug status and has achieved the holy grail of US approval for its treatment for a rare sunlight intolerance disorder. The company is now valued at more than $1bn.
Invex current market capitalization stands at $66 million.
- Forums
- ASX - By Stock
- Why Invex has all the right ingredients to possibly become a takeover target
Dr Boreham’s diagnosis:When it comes to comparative companies,...
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IXC (ASX) to my watchlist
(20min delay)
|
|||||
Last
8.5¢ |
Change
-0.002(2.30%) |
Mkt cap ! $6.388M |
Open | High | Low | Value | Volume |
8.4¢ | 8.5¢ | 8.4¢ | $2.955K | 35K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 94523 | 8.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.9¢ | 58500 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 94523 | 0.085 |
1 | 96433 | 0.084 |
1 | 100000 | 0.083 |
1 | 150000 | 0.082 |
1 | 30306 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.089 | 58500 | 1 |
0.090 | 5000 | 1 |
0.095 | 100000 | 1 |
0.100 | 10000 | 1 |
0.105 | 60000 | 1 |
Last trade - 12.29pm 29/03/2024 (20 minute delay) ? |
|
|||||
Last
8.5¢ |
  |
Change
-0.002 ( 1.19 %) |
|||
Open | High | Low | Volume | ||
8.5¢ | 8.5¢ | 8.5¢ | 5000 | ||
Last updated 12.46pm 29/03/2024 ? |
Featured News
IXC (ASX) Chart |